Drug therapy for AUD may reduce risk of alcohol-related liver disease – Consumer Health News

MONDAY, May 23, 2022 (HealthDay News) — According to a study published online May 20 in Open JAMA Network.

Augustin GL Vannier of Massachusetts General Hospital in Boston and colleagues conducted a retrospective cohort study to examine whether treatment for medical addiction was associated with an altered risk of developing ALD in patients with AUD. The cohort included 9,635 patients with AUD (60.4% male; mean age: 54.8 years).

Researchers found that 11.8% of patients suffered from ALD and 40.5% received medical addiction therapy. Medical addition therapy for AUD was associated with a reduced incidence of ALD in multivariate analyzes (adjusted odds ratio [aOR], 0.37). The association was observed for naltrexone, gabapentin, topiramate, and baclofen (aOR, 0.67, 0.36, 0.47, and 0.57, respectively). In patients with cirrhosis, pharmacotherapy for AUD was associated with a reduced incidence of hepatic decompensation (aOR, 0.35), including naltrexone and gabapentin (aOR, 0.27 and 0.36, respectively). The association persisted even with initiation of medical dependence therapy after diagnosis of cirrhosis (aOR, 0.41).

“Prospective randomized clinical trials are warranted to conclusively assess the benefits of U.S. Food and Drug Administration-approved, off-label AUD pharmacotherapy as prophylaxis and treatment of ALD,” the authors write.

Summary/Full text

Editorial

Comments are closed.